About CytomX Therapeutics
CytomX Therapeutics, Inc. is an oncology-focused biopharmaceutical company. The Company is engaged in the development of a class of antibody therapeutics based on its Probody technology platform. It uses its platform to create cancer immunotherapies against clinically validated targets, as well as to develop cancer therapeutics against a range of targets. A Probody therapeutic consists of three components produced as a single protein by standard antibody production methodology: an active anti-cancer antibody, a mask for the antibody and a protease-cleavable linker. Its Probody product candidate, CX-072, is directed against programmed death-ligand 1 (PD-L1). CX-072 is based on a monoclonal antibody targeting PD-L1. Its product candidate, CX-2009, is directed against the target CD-166. It is developing a programmed cell death protein 1 (PD-1) Probody therapeutic as an additional approach to block the PD-L1/PD-1 pathway. It is also conducting Integrin alpha-3 PDC program.
Industry, Sector and Symbol:
- Sector: Medical
- Industry: Biotechnology
- Sub-Industry: N/A
- Exchange: NASDAQ
- Symbol: CTMX
- Previous Close: $11.66
- 50 Day Moving Average: $11.54
- 200 Day Moving Average: $12.25
- 52-Week Range: $9.10 - $17.79
- Trailing P/E Ratio: N/A
- Foreward P/E Ratio: -5.38
- P/E Growth: -0.47
- Market Cap: $420.44M
- Outstanding Shares: 36,402,000
- Beta: 1.1
- Net Margins: -523.78%
- Return on Equity: -52.50%
- Return on Assets: -28.57%
Companies Related to CytomX Therapeutics:
- Current Ratio: 7.74%
- Quick Ratio: 7.74%
What is CytomX Therapeutics' stock symbol?
CytomX Therapeutics trades on the NASDAQ under the ticker symbol "CTMX."
Where is CytomX Therapeutics' stock going? Where will CytomX Therapeutics' stock price be in 2017?
4 equities research analysts have issued twelve-month target prices for CytomX Therapeutics' stock. Their forecasts range from $19.00 to $22.00. On average, they anticipate CytomX Therapeutics' share price to reach $20.50 in the next year.
When will CytomX Therapeutics announce their earnings?
CytomX Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November, 21st 2016.
What are analysts saying about CytomX Therapeutics stock?
Here are some recent quotes from research analysts about CytomX Therapeutics stock:
According to Zacks Investment Research, "CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California. " (2/14/2017)
Cowen and Company analysts commented, "CTMX announced this morning that the first patient has been dosed in CX-072’s." (2/2/2017)
Cann analysts commented, "We are changing our rating for CytomX, a high-quality development-stage, platform technology company with a strong management team and novel science, from Outperform to Perform, and removing our $22 price target. We anticipate CytomX will launch its first drug, CX-072, in 2023." (1/3/2017)
Who owns CytomX Therapeutics stock?
CytomX Therapeutics' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include FMR LLC (15.00%), Putnam Investments LLC (3.75%), Deerfield Management Co. (2.59%), Perceptive Advisors LLC (2.54%), Franklin Resources Inc. (0.92%) and State Street Corp (0.76%). Company insiders that own CytomX Therapeutics stock include Cynthia J Ladd, Frederick W Gluck, Ix LP Canaan, James E Flynn and Timothy M Shannon.
Who sold CytomX Therapeutics stock? Who is selling CytomX Therapeutics stock?
CytomX Therapeutics' stock was sold by a variety of institutional investors in the last quarter, including Putnam Investments LLC. Company insiders that have sold CytomX Therapeutics stock in the last year include Ix LP Canaan and Timothy M Shannon.
Who bought CytomX Therapeutics stock? Who is buying CytomX Therapeutics stock?
CytomX Therapeutics' stock was purchased by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Renaissance Technologies LLC, Oxford Asset Management, Russell Investments Group Ltd., FMR LLC, Trexquant Investment LP, Harbourvest Partners LLC and Opaleye Management Inc.. Company insiders that have bought CytomX Therapeutics stock in the last two years include Cynthia J Ladd, Frederick W Gluck and James E Flynn.
How do I buy CytomX Therapeutics stock?
Shares of CytomX Therapeutics can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
How much does a share of CytomX Therapeutics stock cost?
One share of CytomX Therapeutics stock can currently be purchased for approximately $11.52.